Commonwealth Equity Services’s Tourmaline Bio TRML Stock Holding History

Commonwealth Equity Services’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,300	Closed	-$40K	–	3933
2023 Q2	$40K	Hold	1,300	–	–	﹤0.01%	3691
2023 Q1	$24	Hold	1,300	–	–	﹤0.01%	3657
2022 Q4	$13K	Hold	1,300	–	–	﹤0.01%	3630
2022 Q3	$34K	Buy	+1,300	New	+$47.4K	﹤0.01%	3520

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Commonwealth Equity Services's TRML Position: Q3 2023 in Review

Commonwealth Equity Services sold out of Tourmaline Bio (TRML) in Q3 2023, closing a stake of 1,300 shares — an estimated $40K sold.

Commonwealth Equity Services first reported a position in TRML in Q3 2022 and held it in 4 quarters. The position peaked at $40K in Q2 2023. 48 funds tracked by Wall St. Rank hold TRML as of Q3 2023.

Commonwealth Equity Services reported no remaining Tourmaline Bio position as of Q3 2023 after selling out during the quarter.
Commonwealth Equity Services sold 1,300 Tourmaline Bio shares in Q3 2023, an estimated $40K.
Commonwealth Equity Services first reported a position in Tourmaline Bio in Q3 2022 and held it in 4 quarters.
Commonwealth Equity Services's Tourmaline Bio position peaked at $40K in Q2 2023.
48 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2023.

Based on Commonwealth Equity Services's 13F filing for Q3 2023, filed 23 Oct 2023.